We have located links that may give you full text access.
A new hope for early T-cell precursor acute lymphoblastic leukemia therapy based on STAT5+ leukemic stem cell targeting.
Journal of Leukocyte Biology 2023 August 23
Leukemia stem cells (LSCs) are known to drive tumor progression, drug resistance, microenvironmental shift and relapse, which would make them a perfect therapeutic target. However, their phenotypic and functional similarity to their normal counterparts leaves limited road maps for their selective elimination. Tremblay and colleagues recently unraveled the fundamental role of overactivated pSTAT5 as a functional marker of ETP-ALL LSCs driving leukemic progression, and highlighted its potential use as a therapeutic target to prevent fatal outcomes.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app